Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Phase III study of NexoBrid meets primary and secondary endpoints

Jan. 23, 2019

Ralexar Therapeutics patents oxysterols receptor LXR-beta agonists

Jan. 17, 2019

Enrollment ongoing in first-in-human study of PBF-1650

Jan. 14, 2019

Blade Therapeutics patents calpain inhibitors

Jan. 11, 2019

Preclinical data presented for sarecycline for the treatment of acne vulgaris

Jan. 11, 2019

Kymab initiates phase II study of KY-1005 in atopic dermatitis

Jan. 9, 2019

Promising phase II data presented for AK-002 in Xolair-naive chronic spontaneous urticaria patients

Jan. 8, 2019

Boehringer Ingelheim patents VNN1 inhibitors

Jan. 3, 2019

Epigenetic protein switches function after development

Jan. 3, 2019

Life Science Institute initiates exploratory clinical trial of CL-2020 in epidermolysis bullosa

Dec. 24, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...